A Legal Test for the Pharmaceutical Company Practice of “Product Hopping”
Bibliographic Data
| ID | 15747882 |
|---|---|
| Authors | Tobin Klusty (corresponding author) |
| Year | 2015 |
| Volume | 17 |
| Issue | 8 |
| Pages | 760-762 |
| Publication date | 2015-08-01 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | The AMA Journal of Ethic (JOURNAL) |
| Journal identifiers | ISSN: 2376-6980 • E-ISSN: 2376-6980 |
| Publisher | American Medical Association (PUBLISHER • US) |
| DOI | 10.1001/journalofethics.2015.17.8.hlaw2-1508 |
| PMID | 26270876 |
| OpenAlex | W938929447 |
| Language | EN |
In New York v. Actavis, the Second Circuit’s ruling forbids product hopping, or extending the monopoly of a patented drug by introducing a new formulation of the drug and discontinuing an older one, if there is evidence that the strategy is coercive and used to restrict fair competition
Business · Product (mathematics · Test (biology · Biomedical Ethics and Regulation · Intellectual Property and Patents · Mathematics · Pharmaceutical Economics and Policy
| Highly cited | No |
|---|